Appendix 1: Market Size in 2013
Rank
|
Total
Market
|
TK(Cr)
|
Market
Share
|
Rating
& Growth %
|
9441
|
8
|
|||
1
|
Square
|
1766
|
18.7
|
7
|
2
|
Incepta Pharma
|
928
|
9.8
|
12
|
3
|
Beximco
|
816
|
8.6
|
5
|
4
|
Opsonin Pharma
|
503
|
5.3
|
10
|
5
|
Renata
|
472
|
5.0
|
10
|
6
|
Eskayef
|
424
|
4.5
|
3
|
7
|
Aristo Pharma
|
401
|
4.2
|
13
|
8
|
A.C.I
|
395
|
4.2
|
3
|
9
|
Drug International
|
366
|
3.9
|
14
|
10
|
ACME
|
361
|
3.8
|
-2
|
11
|
Novo Nordisk
|
224
|
2.4
|
27
|
12
|
Sanofi Aventis
|
213
|
2.3
|
-3
|
13
|
Healthcare Pharma
|
195
|
2.1
|
19
|
14
|
General
|
164
|
1.7
|
15
|
15
|
GlaxoSmithKline
|
162
|
1.7
|
6
|
16
|
Popular Pharma
|
151
|
1.6
|
13
|
17
|
Orion Pharma
|
145
|
1.5
|
-6
|
18
|
Novartis
|
127
|
1.4
|
4
|
19
|
UniMed & Unihealth
|
120
|
1.3
|
20
|
20
|
Sandoz
|
116
|
1.2
|
13
|
Source: Bangladesh Pharmaceutical
Index 2013(1st Quarter)
|
||||
Appendix 2
Source: Bangladesh Pharmaceutical Index 2013(1st Quarter)
Appendix 3
Table: Size and Growth Rate of Manufacturing Sector
(At constant prices of 2005-2006)
(Taka in crore)
Type of Industry
|
2009-10
|
2010-11
|
2011-12
|
2012-2013
|
20013-14
(provisional)
|
Small &
Cottage
|
20039.0
(8.17)
|
21176.0
(5.67)
|
22569.1
(6.58)
|
24557.9
(8.81)
|
26179.4
(6.60)
|
Medium-Large
|
79631.4
(6.26)
|
88475.3
(11.11)
|
97998.3
(10.76)
|
108436.2
(10.65)
|
118364.0
(9.16)
|
Total
|
99670.9
(6.65)
|
109651.4
(10.01)
|
120567.4
(9.96)
|
132994.1
(10.53)
|
144543.8
(8.68)
|
Source:
Bangladesh
Bureau of Statistics. Note: Figures in parentheses indicate rate of growth
Appendix 4
Appendix 5
Appendix: 6
Table of Financial Highlights:
Item
Names
|
2013
|
2012
|
2011
|
Current Assets
|
8,903,422,328
|
8,197,421,953
|
7,148,462,753
|
Total Asset
|
27,470,751,802
|
24,589,810,592
|
23,033,340,533
|
Total liabilities
|
7,695,199,337
|
6,181,648,733
|
5,905,212,356
|
Total Equity
|
24,158,133,743
|
21,473,106,628
|
19,776,290,165
|
Current Liabilities
|
4,382,581,278
|
3,064,944,769
|
2,648,161,988
|
Cash Equivalents
|
592,258,350
|
550,438,345
|
517,051,938
|
Quick Assets (cash & cash
equivalents + accounts receivable + short term investment+ lending amount of
loans, advances, deposits)
|
6,058,187,935
|
5,367,258,182
|
4,530,736,878
|
Accounts Receivable
|
1,249,434,697
|
1,162,404,807
|
978,224,317
|
Net Income
|
1,404,762,780
|
1,319,389,328
|
1,198,525,342
|
Net Sales
|
10,490,699,094
|
9,289,115,284
|
7,890,241,843
|
Equity
|
19,775,552,465
|
18,408,161,859
|
17,128,128,177
|
Long-term Liabilities
|
3,312,618,059
|
3,116,703,964
|
3,257,050,368
|
Operating Income
|
2,324,272,770
|
2,207,879,560
|
1,988,479,698
|
Beginning + Ending Total Assets
|
34,959,718,113
|
32,277,266,419
|
-
|
Gross Profit
|
4,838,800,216
|
4,389,401,427
|
3,786,532,822
|
Earnings before interest & tax
|
2,093,594,171
|
1,909,829,236
|
-
|
Earnings per share (EPS)
|
4.01
|
3.77
|
3.93
|
Market Price Per Share (at end of the year)
|
47.20
|
55.90
|
93.60
|
Working Capital (Current Asset – Current
Liabilities)
|
4,520,841,050
|
5,132,477,184
|
-
|
(Source: Annual
Report of Beximco Pharmaceutical Ltd 2013 &2012)
No comments:
Post a Comment